NLNicolas Leveziel

Nicolas Leveziel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicolas Leveziel has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical and Laboratory Factors Associated With the Severity of Proliferative Sickle Cell Retinopathy in Patients With Sickle Cell Hemoglobin C (SC) and Homozygous Sickle Cell (SS) Disease

    by Nicolas MD Leveziel, Sylvie Bastuji-Garin, Franck Lalloum, Giuseppe Querques, Pascale Benlian, Michel Binaghi, Gabriel Coscas, Gisèle Soubrane, Dora Bachir, Frédéric Galactéros, et al.

    Proliferative sickle cell retinopathy (PSCR) is the most frequent vision-threatening complication of sickle cell disease (SCD). We investigated the relationship between the severity of sickle cell retinopathy in heterozygous (SC) or homozygous (SS) adult SCD patients and the clinical and laboratory data obtained during visits to a national SCD referral center. This retrospective longitudinal analysis included 942 SCD patients (313 patients with SC and 629 with SS disease) with ophthalmologic evaluations who were followed over a 19-year period by a multidisciplinary team in a referral center. PSCR was graded using the Goldberg classification. We identified patient and SCD characteristics associated with sickle cell retinopathy severity using multinomial logistic-regression models. Multivariate analysis associated severe PSCR forms (stages III-V) with older age (p = 0.032), pulmonary involvement (documented pulmonary hypertension with pulmonary arterial pressure ≥40 mm Hg, restrictive syndrome >20%, or previous history of pulmonary embolism diagnosed by vascular imaging) (p = 0.029), deafness or tinnitus (p = 0.026), and no history of osteomyelitis (p = 0.013) for SC patients; and with older age (p < 0.001), male sex (p = 0.003), and acute pyelonephritis (p = 0.04) for SS patients. The model of severe PSCR versus no PSCR showed good calibration and discrimination for SC and SS patients. Awareness of the clinical and laboratory factors significantly associated with severe PSCR in patients with SC or SS SCD may contribute to improved preventive strategies. Abbreviations: CI = confidence interval, HbF = fetal hemoglobin, OR = odds ratio, PSCR = proliferative sickle cell retinopathy, SC = sickle cell hemoglobin C disease, SCD = sickle cell disease, SS = homozygous sickle cell disease.


  • Open Access

    Genetic Factors Associated with Age-Related Macular Degeneration

    by Nicolas Leveziel, Julien Tilleul, Nathalie Puche, Jennyfer Zerbib, Franck Laloum, Giuseppe Querques, Eric H. Souied

    Age-related macular degeneration (AMD) is a complex, multifactorial disease associated with environmental and genetic factors. This review emphasizes the clinical impact of the major genetic factors mainly located in the complement factor H gene and on the 10q26 locus, and their current and future implications for the management of AMD.


  • INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION COMPLICATING PATHOLOGIC MYOPIA

    by Franck Lalloum, Eric H. Souied, Sylvie Bastuji-Garin, Nathalie Puche, Giuseppe Querques, Agnes Glacet-Bernard, Gabriel Coscas, Gisele Soubrane, Nicolas Leveziel

    Purpose: The purpose of this study was to evaluate the efficacy of intravitreal injections of ranibizumab in choroidal neovascularization secondary to pathologic myopia. Methods: A prospective case series of 32 eyes of 32 patients affected with choroidal neovascularization secondary to pathologic myopia treated by intravitreal injections of ranibizumab. Best-corrected visual acuity, fundus examination, fluorescein angiography, indocyanine green angiography, and spectral domain-optical coherence tomography were performed for the diagnosis of myopic choroidal neovascularization. Best-corrected visual acuity and central retinal thickness measurement were performed monthly during the follow-up. Results: The median number of injections was 3 with a median follow-up of 17 months. The median visual acuity at baseline was 20/100 and improved to 20/50 at final examination (P < 0.0001). Best-corrected visual acuity improved by ≥3 lines in 15 of 32 eyes (46.8%). The median central thickness was 336 μm (range, 179-663 μm) at baseline and 233 μm (range, 125-465 μm) at final examination (P < 0.0001). No severe drug-related side effect was reported. Conclusion: In our series of myopic choroidal neovascularization, intravitreal injections of ranibizumab showed visual acuity improvement and retinal thickness reduction. Further prospective multicentric clinical trials are needed to evaluate the safety and the efficacy of this treatment.


  • Spectral domain OCT of exudative AMD

    by N Leveziel, M Voigt, G Coscas, G Soubrane

  • Open Access

    Telangiectasia evaluated with adaptive optics and HR‐OCT

    by K Atmani, N Leveziel, G Soubrane

  • Épidémiologie de la dégénérescence maculaire liée à l’âge

    by N. Leveziel, C. Delcourt, J. Zerbib, H. Dollfus, J. Kaplan, P. Benlian, G. Coscas, E.H. Souied, G. Soubrane